ELIXINOL GLOBAL LIMITED
Q3 FY2019 APPENDIX 4C AND QUARTERLY BUSINESS UPDATE NORMALISED REVENUE GROWTH OF 12% ON Q3 FY2018
Q3 FY2019 group revenue of $9.6m1, represents
normalised revenue growth of 12% on the prior corresponding period (PCP) Q3 FY2018 of $8.6m (normalised to exclude discontinued private label revenue);
represents 3% decline on the prior sequential period Q2 FY2019 of $9.9m; and
9% decline on the prior corresponding period (PCP) Q3 FY2018 of $10.5m.
Elixinol Global Limited (Elixinol Global or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp and emerging medicinal cannabis sectors, is pleased to release its business review and Appendix 4C cash flow statement for the quarter ending 30 September 2019 (Q3 FY2019).
Elixinol’s partnership with PharmaCare continues to grow with additional product development opportunities
Exclusive supply agreement with Pet Releaf for minimum US$18 million over 18 months
Key hires across sales, marketing, eCommerce and operations
For further information please download the attached PDF:
Download this document